EQUITY RESEARCH Healthcare | European Pharmaceuticals | 23 July 2010 ACTELION To be or not to be a biotech company Initiating with a 1-Overweight rating – generic risk…

1. European KOL Compensation Dr. Samuel Dyer CEO and Founder www.MSLWORLD.com 2. Agenda About me, Medical Science Liaison World (MSL World.com) Overall Flat Fee Range Overall…

AN ORGANIZATION STUDY CHAPTER ± I COMPANY PROFILE BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 1 AN ORGANIZATION STUDY 1.1 INTRODUCTION OF ORGANIZATION GSK is one of the…

1. British Columbia, CanadaYour Gateway to North American business opportunitiesPresented by: Bhanu Rahoni Sector Manager - BiotechnologyTechnology, Research & Innovation,British…

1. Scott Brown VP, General Counsel and Global Head of NIBR Patents IPCC PhoenixMarch 2009 Industry Bilski Concerns 2. Novartis Institutes for BioMedical Research (NIBR) *…

1. Ensuring Fast Patient Enrollmentby Placing Clinical Trials in Russiaand UkrainePartnerships in Clinical Trials Russia-CIS2013 2. OCT: CRO in Russia,Central and Eastern…

1. www.katalystwealth.comIPCA Laboratories Ltd (NSE Code: IPCALAB) – Alpha/Alpha + stockrecommendation for Nov’12 2. www.katalystwealth.comContent Index1. Investment…

1. »drug dELivEry roundtABLE »what, in your opinion, is currently the singleDrug Delivery largest trend with respect to the application of drugdelivery technology, specifically…

1. Topic: NUTRACEUTICALS 2. CONTENT HISTORYINTRODUCTIONCONCLUSIONBIBLIOGRAPHY2 3. HISTORY • The Greek physician Hippocrates, often known as the“father of…

Slide 1HOW DO WE GET THE ANTIBIOTICS WE NEED? Opportunities and challenges posed and lessons learned from recent submissions Dr. Flic Gabbay Senior Partner TranScrip Partners…